University of Michigan Rogel Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Michigan Rogel Cancer Center sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
University of Michigan Rogel Cancer Center: 292 sponsored US clinical trials, 45 recruiting.
University of Michigan Rogel Cancer Center sponsors 292 registered US clinical trials on ClinicalTrials.gov, 45 of them currently recruiting, and 167 completed. 4 of these trials are in Phase 3-4 (later-stage) and 182 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
University of Michigan Rogel Cancer Center ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 229 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 2 of 6
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT04574856
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
NCT04140162
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
NCT04477200
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT03842696
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
NCT03787680
APG-115 in Salivary Gland Cancer Trial
NCT03781986
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
NCT02400190
SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners
NCT07481344
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
NCT07526545
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT07682649
Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
NCT07673614
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
NCT07529080
A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families
NCT07542405
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
NCT06617455
Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors
NCT06442891
Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
NCT06046014
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
NCT06378398
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
NCT05780879
Cardiac Rehabilitation to Improve Breast Cancer Outcomes
NCT05867667
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
NCT06228768
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
NCT06073223
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
NCT05583422
Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients
NCT05704790
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
NCT05764005
The Genetic Information and Family Testing (GIFT) Study
NCT05552664
CLEAR Care Companion Application
NCT05578898
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
NCT05169957
Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid
NCT05140252
Michigan Genetic Hereditary Testing (MiGHT)
NCT05162846
Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study
NCT05070299
Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging
NCT04852471
An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors
NCT05030792
Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
NCT04497038
Lighting Intervention for Cancer-related Fatigue
NCT04827446
Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living
NCT04458168
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
NCT04552418
Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors
NCT04827459
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
NCT04754399
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
NCT04595851
Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program
NCT04616651
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT04703920
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
NCT04503668
Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients
NCT04773197
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
NCT04510311
A Pilot Study of Roadmap 2.0 in Oncology Caregivers and Patients
NCT04480541
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
NCT04094844
Testing the Effect of Mindfulness for Prostatectomy Outcomes
NCT04727710
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
NCT04268134
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
NCT04203160
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
NCT04431635
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 126 |
| Phase 3 | 2 |
| Phase 4 | 2 |
What is open in the University of Michigan Rogel Cancer Center pipeline
45 recruiting of 292 indexed (15% open); 167 completed (57%).
Phase mix: 4 late (III/IV) vs 182 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Michigan Rogel Cancer Center: open-pipeline peers nationwide
Peers matched on 292 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Michigan Rogel Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this University of Michigan Rogel Cancer Center page
292 registered trials is a research-attention snapshot, not an endorsement of University of Michigan Rogel Cancer Center or any single study.
- 45 of University of Michigan Rogel Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of Michigan Rogel Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Michigan Rogel Cancer Center pipeline card: 292 registered trials from official public datasets.Report a data error.